STI571: a magic bullet?

被引：29
|
作者：
Verweij, J [1 ]
Judson, I
van Oosterom, A
机构：
[1] Rotterdam Canc Inst, Daniel Den Hoed Klin, Dept Med Oncol, Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, Rotterdam, Netherlands
[3] Royal Marsden Hosp, Dept Med Oncol, Sutton, Surrey, England
[4] Univ Hosp Gasthuisberg, Dept Oncol, B-3000 Louvain, Belgium
来源：
EUROPEAN JOURNAL OF CANCER | 2001年 / 37卷 / 15期
关键词：
D O I：
10.1016/S0959-8049(01)00237-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1816 / 1819
页数：4
相关论文
共 50 条
  • [31] Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
    A Hochhaus
    S Kreil
    AS Corbin
    P La Rosée
    MC Müller
    T Lahaye
    B Hanfstein
    C Schoch
    NCP Cross
    U Berger
    H Gschaidmeier
    BJ Druker
    R Hehlmann
    Leukemia, 2002, 16 : 2190 - 2196
  • [32] STI571: Targeting BCR-ABL as therapy for CML
    Mauro, MJ
    Druker, BJ
    ONCOLOGIST, 2001, 6 (03): : 233 - 238
  • [33] In vitro and in vivo STI571 efficacy in neuroectodermal tumor cells
    Kronnie, GT
    Ricotti, E
    Rinaldi, A
    Creseenzio, N
    Spinelli, M
    Timeus, F
    Rosolen, A
    Basso, G
    BLOOD, 2002, 100 (11) : 220B - 220B
  • [34] STI571 inhibits the activaiton and proliferation of normal T lymphocytes.
    Cwynarski, K
    Laylor, R
    Melo, JV
    Dazzi, F
    BLOOD, 2001, 98 (11) : 256B - 257B
  • [35] STI571 revolution: Can the newer targeted drugs measure up?
    Garber, K
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (13) : 970 - 973
  • [36] Imatinib mesylate (STI571) for myeloid malignancies other than CML
    Krystal, GW
    LEUKEMIA RESEARCH, 2004, 28 : S53 - S59
  • [37] Combination therapy with imatinib mesylate (STI571):: Synopsis of in vitro studies
    Topaly, J
    Zeller, WJ
    Fruehauf, S
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (01) : 3 - 14
  • [38] Selective tyrosinekinase inhibitor imatinib (STI571) in haematological and oncological disease
    Hochhaus, A
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (09) : 451 - 456
  • [39] Some additional cytogenetic aberrations in patients treated with Imatinib (STI571)
    Salamanczuk, Z.
    Jakobczyk, M.
    Sacha, T.
    Skotnicki, A. B.
    CHROMOSOME RESEARCH, 2005, 13 : 171 - 171
  • [40] Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias
    Neil P Shah
    Charles L Sawyers
    Oncogene, 2003, 22 : 7389 - 7395
12345